{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T20:21:33Z","timestamp":1788639693329,"version":"build-2803163510"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40265-024-02077-6","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T09:12:48Z","timestamp":1723194768000},"page":"1199-1218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Anticoagulation in Chronic Kidney Disease"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-6352","authenticated-orcid":false,"given":"Marco","family":"Montomoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris Gonzales","family":"Cand\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Acosta","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Perez","family":"Bernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"issue":"1","key":"2077_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003.","journal-title":"Kidney Int Suppl"},{"issue":"9889","key":"2077_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(13)60595-4.","journal-title":"Lancet"},{"issue":"4","key":"2077_CR3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2215\/CJN.06790712","volume":"8","author":"N Jain","year":"2013","unstructured":"Jain N, Hedayati SS, Sarode R, Banerjee S, Reilly RF. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence? Clin J Am Soc Nephrol. 2013;8(4):665\u201374. https:\/\/doi.org\/10.2215\/CJN.06790712.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2077_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/heartjnl-2012-302818","volume":"99","author":"WE Moody","year":"2013","unstructured":"Moody WE, Edwards NC, Chue CD, Ferro CJ, Townend JN. Arterial disease in chronic kidney disease. Heart. 2013;99(6):365\u201372. https:\/\/doi.org\/10.1136\/heartjnl-2012-302818.","journal-title":"Heart"},{"issue":"7","key":"2077_CR5","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/ndt\/gfab197","volume":"37","author":"I Zamberg","year":"2022","unstructured":"Zamberg I, Assouline-Reinmann M, Carrera E, et al. Epidemiology, thrombolytic management, and outcomes of acute stroke among patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2022;37(7):1289\u2013301. https:\/\/doi.org\/10.1093\/ndt\/gfab197.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"2077_CR6","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1681\/ASN.2015050535","volume":"27","author":"AO Molnar","year":"2016","unstructured":"Molnar AO, Bota SE, Garg AX, et al. The risk of major hemorrhage with CKD. J Am Soc Nephrol. 2016;27(9):2825\u201332. https:\/\/doi.org\/10.1681\/ASN.2015050535.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2077_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.7326\/0003-4819-156-6-201203200-00007","volume":"156","author":"SC Palmer","year":"2012","unstructured":"Palmer SC, Di Micco L, Razavian M, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;156(6):445\u201359. https:\/\/doi.org\/10.7326\/0003-4819-156-6-201203200-00007.","journal-title":"Ann Intern Med"},{"issue":"20","key":"2077_CR8","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/j.jcin.2017.02.047","volume":"10","author":"U Baber","year":"2017","unstructured":"Baber U, Chandrasekhar J, Sartori S, et al. Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the PROMETHEUS study. JACC Cardiovasc Interv. 2017;10(20):2017\u201325. https:\/\/doi.org\/10.1016\/j.jcin.2017.02.047.","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"2077_CR9","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40620-019-00630-1","volume":"32","author":"L Tapoi","year":"2019","unstructured":"Tapoi L, Ureche C, Sascau R, Badarau S, Covic A. Atrial fibrillation and chronic kidney disease conundrum: an update. J Nephrol. 2019;32(6):909\u201317. https:\/\/doi.org\/10.1007\/s40620-019-00630-1.","journal-title":"J Nephrol"},{"issue":"2","key":"2077_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.kint.2018.05.005","volume":"94","author":"C Wanner","year":"2018","unstructured":"Wanner C, Herzog CA, Turakhia MP. Chronic kidney disease and arrhythmias: highlights from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2018;94(2):231\u20134. https:\/\/doi.org\/10.1016\/j.kint.2018.05.005.","journal-title":"Kidney Int"},{"issue":"1","key":"2077_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.gheart.2014.01.004","volume":"9","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Roth GA, Gillum RF, Mensah GA. Global burden of atrial fibrillation in developed and developing nations. Glob Heart. 2014;9(1):113\u20139. https:\/\/doi.org\/10.1016\/j.gheart.2014.01.004.","journal-title":"Glob Heart"},{"issue":"3","key":"2077_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13070","volume":"72","author":"H Zulkifly","year":"2018","unstructured":"Zulkifly H, Lip GYH, Lane DA. Epidemiology of atrial fibrillation. Int J Clin Pract. 2018;72(3): e13070. https:\/\/doi.org\/10.1111\/ijcp.13070.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"2077_CR13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1053\/j.ajkd.2013.02.381","volume":"62","author":"KP Ng","year":"2013","unstructured":"Ng KP, Edwards NC, Lip GY, Townend JN, Ferro CJ. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. Am J Kidney Dis. 2013;62(3):615\u201332. https:\/\/doi.org\/10.1053\/j.ajkd.2013.02.381.","journal-title":"Am J Kidney Dis"},{"key":"2077_CR14","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical practice guideline for the management of glomerular diseases.\u00a0Kidney Int. 2021;100(4S):S1-S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"2077_CR15","doi-asserted-by":"publisher","DOI":"10.1159\/000535546","author":"EJ Elenjickal","year":"2023","unstructured":"Elenjickal EJ, Travlos CK, Marques P, Mavrakanas TA. Anticoagulation in patients with chronic kidney disease. Am J Nephrol. 2023. https:\/\/doi.org\/10.1159\/000535546.","journal-title":"Am J Nephrol"},{"issue":"36","key":"2077_CR16","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739\u201391. https:\/\/doi.org\/10.1093\/eurheartj\/ehx391.","journal-title":"Eur Heart J"},{"issue":"5","key":"2077_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jama.2010.39","volume":"303","author":"BR Hemmelgarn","year":"2010","unstructured":"Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303(5):423\u20139. https:\/\/doi.org\/10.1001\/jama.2010.39.","journal-title":"JAMA"},{"issue":"6","key":"2077_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1161\/CIRCULATIONAHA.113.002385","volume":"129","author":"G Ocak","year":"2014","unstructured":"Ocak G, Vossen CY, Lijfering WM, et al. Role of hemostatic factors on the risk of venous thrombosis in people with impaired kidney function. Circulation. 2014;129(6):683\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.002385.","journal-title":"Circulation"},{"issue":"16","key":"2077_CR19","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1161\/CIRCULATIONAHA.112.113944","volume":"126","author":"BK Mahmoodi","year":"2012","unstructured":"Mahmoodi BK, Gansevoort RT, N\u00e6ss IA, et al. Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts. Circulation. 2012;126(16):1964\u201371. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.113944.","journal-title":"Circulation"},{"issue":"7","key":"2077_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1105594","volume":"367","author":"JB Olesen","year":"2012","unstructured":"Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease[published correction appears in N Engl J Med. 2012 Dec 6;367(23):2262]. N Engl J Med. 2012;367(7):625\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1105594.","journal-title":"N Engl J Med"},{"issue":"3","key":"2077_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1046\/j.1525-139x.2003.16048.x","volume":"16","author":"LF Casserly","year":"2003","unstructured":"Casserly LF, Dember LM. Thrombosis in end-stage renal disease. Semin Dial. 2003;16(3):245\u201356. https:\/\/doi.org\/10.1046\/j.1525-139x.2003.16048.x.","journal-title":"Semin Dial"},{"issue":"1","key":"2077_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/ndt\/gft209","volume":"29","author":"J Lutz","year":"2014","unstructured":"Lutz J, Menke J, Sollinger D, Schinzel H, Th\u00fcrmel K. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014;29(1):29\u201340. https:\/\/doi.org\/10.1093\/ndt\/gft209.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2077_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/toxins10010033","volume":"10","author":"R Vanholder","year":"2018","unstructured":"Vanholder R, Pletinck A, Schepers E, Glorieux G. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins (Basel). 2018;10(1):33. https:\/\/doi.org\/10.3390\/toxins10010033.","journal-title":"Toxins (Basel)."},{"key":"2077_CR24","doi-asserted-by":"publisher","unstructured":"Baaten CCFMJ, Sternkopf M, Henning T, Marx N, Jankowski J, Noels H. Platelet function in CKD: a systematic review and meta-analysis. J Am Soc Nephrol. 2021;32(7):1583-1598. https:\/\/doi.org\/10.1681\/ASN.2020101440","DOI":"10.1681\/ASN.2020101440"},{"issue":"4","key":"2077_CR25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11739-011-0705-5","volume":"8","author":"C Camaioni","year":"2013","unstructured":"Camaioni C, Gustapane M, Cialdella P, Della Bona R, Biasucci LM. Microparticles and microRNAs: new players in the complex field of coagulation. Intern Emerg Med. 2013;8(4):291\u20136. https:\/\/doi.org\/10.1007\/s11739-011-0705-5.","journal-title":"Intern Emerg Med"},{"issue":"4","key":"2077_CR26","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1160\/TH12-03-0153","volume":"108","author":"H Pl\u00e9","year":"2012","unstructured":"Pl\u00e9 H, Maltais M, Corduan A, Rousseau G, Madore F, Provost P. Alteration of the platelet transcriptome in chronic kidney disease. Thromb Haemost. 2012;108(4):605\u201315. https:\/\/doi.org\/10.1160\/TH12-03-0153.","journal-title":"Thromb Haemost"},{"issue":"5","key":"2077_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1055\/s-2004-835678","volume":"30","author":"P Boccardo","year":"2004","unstructured":"Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost. 2004;30(5):579\u201389. https:\/\/doi.org\/10.1055\/s-2004-835678.","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"2077_CR28","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.ackd.2010.06.002","volume":"17","author":"WE Dager","year":"2010","unstructured":"Dager WE, Kiser TH. Systemic anticoagulation considerations in chronic kidney disease. Adv Chronic Kidney Dis. 2010;17(5):420\u20137. https:\/\/doi.org\/10.1053\/j.ackd.2010.06.002.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"8","key":"2077_CR29","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s11739-017-1753-2","volume":"12","author":"S Sciascia","year":"2017","unstructured":"Sciascia S, Radin M, Schreiber K, Fenoglio R, Baldovino S, Roccatello D. Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. Intern Emerg Med. 2017;12(8):1101\u20138. https:\/\/doi.org\/10.1007\/s11739-017-1753-2.","journal-title":"Intern Emerg Med"},{"issue":"20","key":"2077_CR30","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.3390\/cells11203214","volume":"11","author":"M Heestermans","year":"2022","unstructured":"Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, Bertoletti L. Anticoagulants: a short history, their mechanism of action, pharmacology, and indications. Cells. 2022;11(20):3214. https:\/\/doi.org\/10.3390\/cells11203214.","journal-title":"Cells"},{"issue":"4","key":"2077_CR31","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.kint.2019.11.027","volume":"97","author":"VK Derebail","year":"2020","unstructured":"Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2020;97(4):664\u201375. https:\/\/doi.org\/10.1016\/j.kint.2019.11.027.","journal-title":"Kidney Int"},{"issue":"10","key":"2077_CR32","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1093\/ndt\/gfi004","volume":"20","author":"GR Hetzel","year":"2005","unstructured":"Hetzel GR, Sucker C. The heparins: all a nephrologist should know. Nephrol Dial Transplant. 2005;20(10):2036\u201342. https:\/\/doi.org\/10.1093\/ndt\/gfi004.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2077_CR33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/ckj\/sfu080","volume":"7","author":"S Hughes","year":"2014","unstructured":"Hughes S, Szeki I, Nash MJ, Thachil J. Anticoagulation in chronic kidney disease patients-the practical aspects. Clin Kidney J. 2014;7(5):442\u20139. https:\/\/doi.org\/10.1093\/ckj\/sfu080.","journal-title":"Clin Kidney J"},{"issue":"5","key":"2077_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/MCP.0b013e328216430d","volume":"13","author":"M Crowther","year":"2007","unstructured":"Crowther M, Lim W. Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med. 2007;13(5):409\u201313. https:\/\/doi.org\/10.1097\/MCP.0b013e328216430d.","journal-title":"Curr Opin Pulm Med"},{"issue":"4","key":"2077_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2165\/00002018-200528040-00005","volume":"28","author":"I Gouin-Thibault","year":"2005","unstructured":"Gouin-Thibault I, Pautas E, Siguret V. Safety profile of different low-molecular weight heparins used at therapeutic dose. Drug Saf. 2005;28(4):333\u201349. https:\/\/doi.org\/10.2165\/00002018-200528040-00005.","journal-title":"Drug Saf"},{"issue":"5","key":"2077_CR36","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.amjmed.2012.09.021","volume":"126","author":"J Trujillo-Santos","year":"2013","unstructured":"Trujillo-Santos J, Schellong S, Falga C, et al. Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function. Am J Med. 2013;126(5):425-434.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2012.09.021.","journal-title":"Am J Med"},{"issue":"8","key":"2077_CR37","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/clc.23196","volume":"42","author":"V Aursulesei","year":"2019","unstructured":"Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol. 2019;42(8):774\u201382. https:\/\/doi.org\/10.1002\/clc.23196.","journal-title":"Clin Cardiol"},{"issue":"9","key":"2077_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","volume":"144","author":"W Lim","year":"2006","unstructured":"Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144(9):673\u201384. https:\/\/doi.org\/10.7326\/0003-4819-144-9-200605020-00011.","journal-title":"Ann Intern Med"},{"issue":"22","key":"2077_CR39","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","volume":"2","author":"DM Witt","year":"2018","unstructured":"Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257\u201391. https:\/\/doi.org\/10.1182\/bloodadvances.2018024893.","journal-title":"Blood Adv"},{"issue":"13","key":"2077_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden B. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13): e017559. https:\/\/doi.org\/10.1161\/JAHA.120.017559.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"2077_CR41","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.3390\/molecules25061465","volume":"25","author":"K Kasperkiewicz","year":"2020","unstructured":"Kasperkiewicz K, Ponczek MB, Owczarek J, Guga P, Budzisz E. Antagonists of vitamin K-popular coumarin drugs and new synthetic and natural coumarin derivatives. Molecules. 2020;25(6):1465. https:\/\/doi.org\/10.3390\/molecules25061465.","journal-title":"Molecules"},{"key":"2077_CR42","doi-asserted-by":"publisher","unstructured":"Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [published correction appears in Chest. 2005 Jan;127(1):415-6. Dosage error in article text].\u00a0Chest. 2004;126(3 Suppl):204S-233S. https:\/\/doi.org\/10.1378\/chest.126.3_suppl.204S","DOI":"10.1378\/chest.126.3_suppl.204S"},{"issue":"4","key":"2077_CR43","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1681\/ASN.2008070802","volume":"20","author":"NA Limdi","year":"2009","unstructured":"Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009;20(4):912\u201321. https:\/\/doi.org\/10.1681\/ASN.2008070802.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2077_CR44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/nu11010168","volume":"11","author":"M Cozzolino","year":"2019","unstructured":"Cozzolino M, Mangano M, Galassi A, Ciceri P, Messa P, Nigwekar S. Vitamin K in chronic kidney disease. Nutrients. 2019;11(1):168. https:\/\/doi.org\/10.3390\/nu11010168.","journal-title":"Nutrients"},{"issue":"4","key":"2077_CR45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2175","volume":"3","author":"MS Randhawa","year":"2020","unstructured":"Randhawa MS, Vishwanath R, Rai MP, et al. Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(4): e202175. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.2175.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"2077_CR46","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1681\/ASN.2009030319","volume":"20","author":"KE Chan","year":"2009","unstructured":"Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20(10):2223\u201333. https:\/\/doi.org\/10.1681\/ASN.2009030319.","journal-title":"J Am Soc Nephrol"},{"issue":"13","key":"2077_CR47","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.2165\/11635730-000000000-00000","volume":"72","author":"BK Poulsen","year":"2012","unstructured":"Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs. 2012;72(13):1739\u201353. https:\/\/doi.org\/10.2165\/11635730-000000000-00000.","journal-title":"Drugs"},{"issue":"11","key":"2077_CR48","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1177\/1060028013504741","volume":"47","author":"T Hellwig","year":"2013","unstructured":"Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother. 2013;47(11):1478\u201387. https:\/\/doi.org\/10.1177\/1060028013504741.","journal-title":"Ann Pharmacother"},{"issue":"13","key":"2077_CR49","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1161\/CIRCULATIONAHA.112.105908","volume":"126","author":"V Fuster","year":"2012","unstructured":"Fuster V, Bhatt DL, Califf RM, et al. Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation. 2012;126(13):1645\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.105908.","journal-title":"Circulation"},{"issue":"1","key":"2077_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/j.ajkd.2015.01.022","volume":"66","author":"AS De Vriese","year":"2015","unstructured":"De Vriese AS, Caluw\u00e9 R, Bailleul E, et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis. 2015;66(1):91\u20138. https:\/\/doi.org\/10.1053\/j.ajkd.2015.01.022.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2077_CR51","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1160\/TH14-06-0547","volume":"113","author":"DA Parasrampuria","year":"2015","unstructured":"Parasrampuria DA, Marbury T, Matsushima N, et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis [published correction appears in Thromb Haemost. 2017 Apr 3;117(4):821]. Thromb Haemost. 2015;113(4):719\u201327. https:\/\/doi.org\/10.1160\/TH14-06-0547.","journal-title":"Thromb Haemost"},{"issue":"6","key":"2077_CR52","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/pace.13331","volume":"41","author":"R Chokesuwattanaskul","year":"2018","unstructured":"Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, Kaewput W, Pachariyanon P, Cheungpasitporn W. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis [published correction appears in Pacing Clin Electrophysiol. 2018 Jul;41(7):879]. Pacing Clin Electrophysiol. 2018;41(6):627\u201334. https:\/\/doi.org\/10.1111\/pace.13331.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"11","key":"2077_CR53","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","volume":"131","author":"KE Chan","year":"2015","unstructured":"Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131(11):972\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.014113.","journal-title":"Circulation"},{"issue":"1","key":"2077_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13318-018-0501-y","volume":"44","author":"R Padrini","year":"2019","unstructured":"Padrini R. Clinical pharmacokinetics and pharmacodynamics of direct oral anticoagulants in patients with renal failure. Eur J Drug Metab Pharmacokinet. 2019;44(1):1\u201312. https:\/\/doi.org\/10.1007\/s13318-018-0501-y.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"6","key":"2077_CR55","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ahj.2010.03.027","volume":"159","author":"EZ Soliman","year":"2010","unstructured":"Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC) [published correction appears in Am Heart J. 2011 Oct;162(4):794] [published correction appears in Am Heart J. 2010 Dec 1;160(6):1190]. Am Heart J. 2010;159(6):1102\u20137. https:\/\/doi.org\/10.1016\/j.ahj.2010.03.027.","journal-title":"Am Heart J"},{"key":"2077_CR56","doi-asserted-by":"publisher","unstructured":"Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC [published correction appears in Eur Heart J. 2021 Feb 1;42(5):507] [published correction appears in Eur Heart J. 2021 Feb 1;42(5):546-547] [published correction appears in Eur Heart J. 2021 Oct 21;42(40):4194].\u00a0Eur Heart J. 2021;42(5):373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612","DOI":"10.1093\/eurheartj\/ehaa612"},{"issue":"12","key":"2077_CR57","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.3390\/healthcare10122566","volume":"10","author":"M Montomoli","year":"2022","unstructured":"Montomoli M, Roca L, Rivera M, et al. Oral anticoagulation in patients with chronic kidney disease and non-valvular atrial fibrillation: the FAERC study. Healthcare (Basel). 2022;10(12):2566. https:\/\/doi.org\/10.3390\/healthcare10122566.","journal-title":"Healthcare (Basel)."},{"issue":"5","key":"2077_CR58","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.112.123992","volume":"127","author":"N Bansal","year":"2013","unstructured":"Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013;127(5):569\u201374. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.123992.","journal-title":"Circulation"},{"issue":"7","key":"2077_CR59","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","volume":"65","author":"TF Chao","year":"2015","unstructured":"Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65(7):635\u201342. https:\/\/doi.org\/10.1016\/j.jacc.2014.11.046.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2077_CR60","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrneph.2018.19","volume":"14","author":"TS Potpara","year":"2018","unstructured":"Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol. 2018;14(5):337\u201351. https:\/\/doi.org\/10.1038\/nrneph.2018.19.","journal-title":"Nat Rev Nephrol"},{"issue":"FI1","key":"2077_CR61","doi-asserted-by":"publisher","first-page":"f3","DOI":"10.1093\/ehjcvp\/pvaa063","volume":"7","author":"CJ Lee","year":"2021","unstructured":"Lee CJ, Toft-Petersen AP, Ozenne B, et al. Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach. Eur Heart J Cardiovasc Pharmacother. 2021;7(FI1):f3\u201310. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa063.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"5","key":"2077_CR62","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1378\/chest.13-0054","volume":"144","author":"S Apostolakis","year":"2013","unstructured":"Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest. 2013;144(5):1555\u201363. https:\/\/doi.org\/10.1378\/chest.13-0054.","journal-title":"Chest"},{"issue":"4","key":"2077_CR63","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/1755-5922.12129","volume":"33","author":"BA Steinberg","year":"2015","unstructured":"Steinberg BA, Greiner MA, Hammill BG, et al. Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. Cardiovasc Ther. 2015;33(4):177\u201383. https:\/\/doi.org\/10.1111\/1755-5922.12129.","journal-title":"Cardiovasc Ther"},{"issue":"12","key":"2077_CR64","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1055\/s-0038-1675400","volume":"118","author":"ED Borre","year":"2018","unstructured":"Borre ED, Goode A, Raitz G, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost. 2018;118(12):2171\u201387. https:\/\/doi.org\/10.1055\/s-0038-1675400.","journal-title":"Thromb Haemost"},{"key":"2077_CR65","doi-asserted-by":"crossref","unstructured":"AJ Camm, GY Lip, Caterina R De, I Savelieva, D Atar, SH Hohnloser, G Hindricks, P Kirchhof. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J\u00a033, 2719-47 (2012).","DOI":"10.1016\/j.rec.2012.11.003"},{"issue":"12","key":"2077_CR66","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.123.064556","volume":"148","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal R, Ruff CT, Virdone S, et al. Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants. Circulation. 2023;148(12):936\u201346. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064556.","journal-title":"Circulation"},{"issue":"4","key":"2077_CR67","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1378\/chest.15-1719","volume":"149","author":"K Dahal","year":"2016","unstructured":"Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest. 2016;149(4):951\u20139. https:\/\/doi.org\/10.1378\/chest.15-1719.","journal-title":"Chest"},{"issue":"5","key":"2077_CR68","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1053\/j.ajkd.2014.11.004","volume":"65","author":"NA Limdi","year":"2015","unstructured":"Limdi NA, Nolin TD, Booth SL, et al. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. Am J Kidney Dis. 2015;65(5):701\u20139. https:\/\/doi.org\/10.1053\/j.ajkd.2014.11.004.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"2077_CR69","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med"},{"issue":"12","key":"2077_CR70","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010 Nov 4;363(19):1877]. N Engl J Med. 2009;361(12):1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"issue":"11","key":"2077_CR71","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"},{"issue":"22","key":"2077_CR72","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907.","journal-title":"N Engl J Med"},{"issue":"9921","key":"2077_CR73","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0.","journal-title":"Lancet"},{"issue":"11","key":"2077_CR74","doi-asserted-by":"publisher","first-page":"11373","DOI":"10.1002\/14651858.CD011373.pub2","volume":"11","author":"M Kimachi","year":"2017","unstructured":"Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev. 2017;11(11):11373. https:\/\/doi.org\/10.1002\/14651858.CD011373.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"2077_CR75","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","volume":"141","author":"JW Stanifer","year":"2020","unstructured":"Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020;141(17):1384\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044059.","journal-title":"Circulation"},{"issue":"21","key":"2077_CR76","doi-asserted-by":"publisher","first-page":"e2421","DOI":"10.1212\/WNL.0000000000007534","volume":"92","author":"K Malhotra","year":"2019","unstructured":"Malhotra K, Ishfaq MF, Goyal N, et al. Oral anticoagulation in patients with chronic kidney disease: a systematic review and meta-analysis. Neurology. 2019;92(21):e2421\u201331. https:\/\/doi.org\/10.1212\/WNL.0000000000007534.","journal-title":"Neurology"},{"issue":"23","key":"2077_CR77","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","volume":"147","author":"J Harrington","year":"2023","unstructured":"Harrington J, Carnicelli AP, Hua K, et al. Direct oral anticoagulants versus warfarin across the spectrum of kidney function: patient-level network meta-analyses from COMBINE AF. Circulation. 2023;147(23):1748\u201357. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062752.","journal-title":"Circulation"},{"key":"2077_CR78","doi-asserted-by":"publisher","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, et al. & the Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.\u00a0Kidney Int. 2024;105(4S):S117-S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"2077_CR79","doi-asserted-by":"crossref","unstructured":"Xiaoxi Yao, Jonathan W. Inselman, Joseph S. Ross, Rima Izem, David J. Graham, David B. Martin, Aliza M. Thompson, Mary Ross Southworth, Konstantinos C. Siontis, Che G. Ngufor, Karl A. Nath, Nihar R. Desai, Brahmajee K. Nallamothu, Rajiv Saran, Nilay D. Shah, Peter A. Noseworthy. Comparative effectiveness and safety of oral anticoagulants across kidney function in patients with atrial fibrillation.\u00a0Circ Cardiovasc Quality Outcomes\u00a013\u00a0Ovid Technologies (Wolters Kluwer Health), 2020.","DOI":"10.1161\/CIRCOUTCOMES.120.006515"},{"issue":"4","key":"2077_CR80","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1681\/ASN.2007111207","volume":"20","author":"H Reinecke","year":"2009","unstructured":"Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol. 2009;20(4):705\u201311. https:\/\/doi.org\/10.1681\/ASN.2007111207.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2077_CR81","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1093\/ndt\/gfs416","volume":"27","author":"D Zimmerman","year":"2012","unstructured":"Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis [published correction appears in Nephrol Dial Transplant. 2014 Nov;29(11):2152]. Nephrol Dial Transplant. 2012;27(10):3816\u201322. https:\/\/doi.org\/10.1093\/ndt\/gfs416.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2077_CR82","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/sdi.12380","volume":"28","author":"M Kessler","year":"2015","unstructured":"Kessler M, Moureau F, Nguyen P. Anticoagulation in chronic hemodialysis: progress toward an optimal approach. Semin Dial. 2015;28(5):474\u201389. https:\/\/doi.org\/10.1111\/sdi.12380.","journal-title":"Semin Dial"},{"key":"2077_CR83","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae029","author":"K Deok-Gie","year":"2024","unstructured":"Deok-Gie K, Sung Hwa K, Sung Yong P, Byoung Geun H, Jae Seok K, Jae Won Y, Young Jun P, Jun YL. Anticoagulation in patients with end-stage kidney disease and atrial fibrillation: a national population-based study. Clin Kidney J. 2024. https:\/\/doi.org\/10.1093\/ckj\/sfae029.","journal-title":"Clin Kidney J"},{"issue":"23","key":"2077_CR84","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","volume":"146","author":"SD Pokorney","year":"2022","unstructured":"Pokorney SD, Chertow GM, Al-Khalidi HR, et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation. 2022;146(23):1735\u201345. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054990.","journal-title":"Circulation"},{"issue":"11","key":"2077_CR85","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/ndt\/gfab060","volume":"37","author":"AS De Vriese","year":"2022","unstructured":"De Vriese AS, Heine G. Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion. Nephrol Dial Transplant. 2022;37(11):2072\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfab060.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2077_CR86","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.cjca.2017.02.004","volume":"33","author":"Z Harel","year":"2017","unstructured":"Harel Z, Chertow GM, Shah PS, et al. Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta-analysis. Can J Cardiol. 2017;33(6):737\u201346. https:\/\/doi.org\/10.1016\/j.cjca.2017.02.004.","journal-title":"Can J Cardiol"},{"issue":"1","key":"2077_CR87","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12882-016-0368-6","volume":"17","author":"J Tan","year":"2016","unstructured":"Tan J, Liu S, Segal JB, Alexander GC, McAdams-DeMarco M. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrol. 2016;17(1):157. https:\/\/doi.org\/10.1186\/s12882-016-0368-6.","journal-title":"BMC Nephrol"},{"issue":"6","key":"2077_CR88","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1681\/ASN.2020111566","volume":"32","author":"AS De Vriese","year":"2021","unstructured":"De Vriese AS, Caluw\u00e9 R, Van Der Meersch H, De Boeck K, De Bacquer D. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol. 2021;32(6):1474\u201383. https:\/\/doi.org\/10.1681\/ASN.2020111566.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2077_CR89","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","volume":"147","author":"H Reinecke","year":"2023","unstructured":"Reinecke H, Engelbertz C, Bauersachs R, et al. A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation. 2023;147(4):296\u2013309. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062779.","journal-title":"Circulation"},{"issue":"1","key":"2077_CR90","doi-asserted-by":"publisher","first-page":"2349114","DOI":"10.1080\/0886022X.2024.2349114","volume":"46","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang J, Shen N, Jiang J, Xie Y. Safety and efficacy of apixaban versus vitamin K antagonists in patients undergoing dialysis: a systematic review and meta-analysis. Ren Fail. 2024;46(1):2349114. https:\/\/doi.org\/10.1080\/0886022X.2024.2349114.","journal-title":"Ren Fail"},{"key":"2077_CR91","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae042","author":"SM Laville","year":"2024","unstructured":"Laville SM, Couchoud C, Bauwens M, et al. Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in patients on chronic dialysis: a nationwide registry study. Nephrol Dial Transplant. 2024. https:\/\/doi.org\/10.1093\/ndt\/gfae042.","journal-title":"Nephrol Dial Transplant"},{"key":"2077_CR92","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijcard.2016.01.003","volume":"207","author":"J Kefer","year":"2016","unstructured":"Kefer J, Tzikas A, Freixa X, et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Int J Cardiol. 2016;207:335\u201340. https:\/\/doi.org\/10.1016\/j.ijcard.2016.01.003.","journal-title":"Int J Cardiol"},{"issue":"12","key":"2077_CR93","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1093\/ckj\/sfad221","volume":"16","author":"S Genovesi","year":"2023","unstructured":"Genovesi S, Porcu L, Rebora P, et al. Long-term safety and efficacy of left atrial appendage occlusion in dialysis patients with atrial fibrillation: a multi-center, prospective, open label, observational study. Clin Kidney J. 2023;16(12):2683\u201392. https:\/\/doi.org\/10.1093\/ckj\/sfad221.","journal-title":"Clin Kidney J"},{"issue":"6","key":"2077_CR94","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.semnephrol.2018.08.006","volume":"38","author":"A Hu","year":"2018","unstructured":"Hu A, Niu J, Winkelmayer WC. Oral anticoagulation in patients with end-stage kidney disease on dialysis and atrial fibrillation. Semin Nephrol. 2018;38(6):618\u201328. https:\/\/doi.org\/10.1016\/j.semnephrol.2018.08.006.","journal-title":"Semin Nephrol"},{"issue":"12","key":"2077_CR95","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1097\/JCMA.0000000000000417","volume":"83","author":"YH Lee","year":"2020","unstructured":"Lee YH, Chen YT, Chang CC, Hsu CY, Su YW, Li SY, Huang CC, Leu HB, Huang PH, Chen JW, Lin SJ. Risk of ischemic stroke in patients with end-stage renal disease receiving peritoneal dialysis with new-onset atrial fibrillation. J Chin Med Assoc. 2020;83(12):1066\u201370. https:\/\/doi.org\/10.1097\/JCMA.0000000000000417.","journal-title":"J Chin Med Assoc"},{"issue":"12","key":"2077_CR96","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019596","volume":"10","author":"CH Chang","year":"2021","unstructured":"Chang CH, Fan PC, Lin YS, Chen SW, Wu M, Lin MS, Lu CH, Chang PC, Hsieh MJ, Wang CY, Wang CL, Chu PH, Wu VC. Dialysis mode and associated outcomes in patients with end-stage renal disease and atrial fibrillation: a 14-year nationwide cohort study. J Am Heart Assoc. 2021;10(12): e019596. https:\/\/doi.org\/10.1161\/JAHA.120.019596.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"2077_CR97","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40256-019-00347-3","volume":"19","author":"D Phan","year":"2019","unstructured":"Phan D, Yang SJ, Shen AY, Lee MS. Effect of warfarin on ischemic stroke, bleeding, and mortality in patients with atrial fibrillation receiving peritoneal dialysis. Am J Cardiovasc Drugs. 2019;19(5):509\u201315. https:\/\/doi.org\/10.1007\/s40256-019-00347-3.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"23","key":"2077_CR98","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","volume":"64","author":"AN Bonde","year":"2014","unstructured":"Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason GH, Torp-Pedersen C, Olesen JB. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014;64(23):2471\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2014.09.051.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"2077_CR99","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","volume":"138","author":"KC Siontis","year":"2018","unstructured":"Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138(15):1519\u201329. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035418.","journal-title":"Circulation"},{"issue":"8","key":"2077_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100646","volume":"5","author":"WW Fung","year":"2023","unstructured":"Fung WW, Cheng PM, Ng JK, Chan GC, Chow KM, Li PK, Szeto CC. Pharmacokinetics of apixaban among peritoneal dialysis patients. Kidney Med. 2023;5(8): 100646. https:\/\/doi.org\/10.1016\/j.xkme.2023.100646.","journal-title":"Kidney Med."},{"key":"2077_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2023.06.004","author":"E P\u00e9rez-Bernat","year":"2023","unstructured":"P\u00e9rez-Bernat E, Vi\u00f1as M, Vera M, Gonz\u00e1lez-Rico M, Montomoli M, Astudillo-Cort\u00e9s E, Quevedo-Reina JC, Garc\u00eda-M\u00e9ndez I, Martinez-Losa A, Rama-Arias I, Maldonado-Mart\u00edn M, Munar M, Cerrato AO, Beltr\u00e1n-Catal\u00e1n S, Del Peso G, Cases A, G\u00f3rriz JL. Fibrilaci\u00f3n auricular no valvular en pacientes en di\u00e1lisis peritoneal: prevalencia, tratamiento y profesionales implicados. Nefrologia. 2023. https:\/\/doi.org\/10.1016\/j.nefro.2023.06.004.","journal-title":"Nefrologia"},{"issue":"12","key":"2077_CR102","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1097\/TP.0000000000003168","volume":"104","author":"J Leon","year":"2020","unstructured":"Leon J, Sabbah L, Aubert O, Anglicheau D, Delavenne X, Zuber J, Amrouche L, Scemla A, Giura G, Divard G, Legendre C, Sberro-Soussan R. Efficacy and safety of direct oral anticoagulants in kidney transplantation: a single-center pilot experience. Transplantation. 2020;104(12):2625\u201331. https:\/\/doi.org\/10.1097\/TP.0000000000003168.","journal-title":"Transplantation"},{"issue":"23","key":"2077_CR103","doi-asserted-by":"publisher","first-page":"12808","DOI":"10.3390\/ijms222312808","volume":"22","author":"M Zhao","year":"2021","unstructured":"Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, He L, Qin S. Cytochrome p450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021;22(23):12808. https:\/\/doi.org\/10.3390\/ijms222312808.","journal-title":"Int J Mol Sci"},{"key":"2077_CR104","doi-asserted-by":"publisher","unstructured":"Yanik MV, Irvin MR, Beasley TM, Jacobson PA, Julian BA, Limdi NA. Influence of kidney transplant status on warfarin dose, anticoagulation control, and risk of hemorrhage. Pharmacotherapy. 2017 Nov;37(11):1366-1373. https:\/\/doi.org\/10.1002\/phar.2032. Epub 2017 Nov 2. PMID: 28949423; PMCID: PMC5681429.","DOI":"10.1002\/phar.2032"},{"issue":"5","key":"2077_CR105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285412","volume":"18","author":"C Firth","year":"2023","unstructured":"Firth C, Shamoun F, Apolinario M, Lim ES, Zhang N, Keddis MT. Safety and mortality outcomes for direct oral anticoagulants in renal transplant recipients. PLoS ONE. 2023;18(5): e0285412. https:\/\/doi.org\/10.1371\/journal.pone.0285412.","journal-title":"PLoS ONE"},{"key":"2077_CR106","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejim.2023.08.003","volume":"119","author":"F Santoro","year":"2024","unstructured":"Santoro F, Casanova A, Simone S, Alfieri C, Falcone A, Dello Strologo A, Grandinetti V, Busutti M, Comai G, Marvulli TM, Zippo MG, Castellano G, La Manna G, Gesualdo L, Giuseppe G, Pesce F. Immunosuppressive therapy and oral anticoagulation in kidney transplant recipients: direct oral anticoagulants versus vitamin-k antagonists. Eur J Intern Med. 2024;119:71\u20137. https:\/\/doi.org\/10.1016\/j.ejim.2023.08.003.","journal-title":"Eur J Intern Med"},{"issue":"10","key":"2077_CR107","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidb\u00fcchel H. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612\u201376. https:\/\/doi.org\/10.1093\/europace\/euab065.","journal-title":"Europace"},{"issue":"3","key":"2077_CR108","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/ckj\/sfy133","volume":"12","author":"KB de Aquino Moura","year":"2019","unstructured":"de Aquino Moura KB, Behrens PMP, Pirolli R, et al. Anticoagulant-related nephropathy: systematic review and meta-analysis. Clin Kidney J. 2019;12(3):400\u20137. https:\/\/doi.org\/10.1093\/ckj\/sfy133.","journal-title":"Clin Kidney J"},{"issue":"2","key":"2077_CR109","doi-asserted-by":"publisher","first-page":"c142","DOI":"10.1159\/000312877","volume":"115","author":"SV Brodsky","year":"2010","unstructured":"Brodsky SV, Collins M, Park E, et al. Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract. 2010;115(2):c142\u20136. https:\/\/doi.org\/10.1159\/000312877.","journal-title":"Nephron Clin Pract"},{"issue":"21","key":"2077_CR110","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","volume":"70","author":"X Yao","year":"2017","unstructured":"Yao X, Tangri N, Gersh BJ, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017;70(21):2621\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2017.09.1087.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2077_CR111","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.116.021890","volume":"134","author":"CB Fordyce","year":"2016","unstructured":"Fordyce CB, Hellkamp AS, Lokhnygina Y, et al. On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: Insights From ROCKET AF [published correction appears in Circulation. 2016 Aug 23;134(8):e114] [published correction appears in Circulation. 2020 Feb 25;141(8):e98]. Circulation. 2016;134(1):37\u201347. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021890.","journal-title":"Circulation"},{"issue":"2","key":"2077_CR112","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/j.ajkd.2020.12.004","volume":"78","author":"JB Wetmore","year":"2021","unstructured":"Wetmore JB, Yan H, Herzog CA, Weinhandl E, Reyes JL, Roetker NS. CKD progression in medicare beneficiaries with nonvalvular atrial fibrillation treated with apixaban versus warfarin. Am J Kidney Dis. 2021;78(2):180\u20139. https:\/\/doi.org\/10.1053\/j.ajkd.2020.12.004.","journal-title":"Am J Kidney Dis"},{"issue":"23","key":"2077_CR113","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/j.jacc.2015.03.577","volume":"65","author":"M B\u00f6hm","year":"2015","unstructured":"B\u00f6hm M, Ezekowitz MD, Connolly SJ, et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol. 2015;65(23):2481\u201393. https:\/\/doi.org\/10.1016\/j.jacc.2015.03.577.","journal-title":"J Am Coll Cardiol"},{"key":"2077_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100813","author":"R Kreutz","year":"2024","unstructured":"Kreutz R, Deray G, Floege J, et al. Rivaroxaban vs vitamin K antagonist in patients with atrial fibrillation and advanced chronic kidney disease. JACC Adv. 2024. https:\/\/doi.org\/10.1016\/j.jacadv.2023.100813.","journal-title":"JACC Adv."},{"issue":"4","key":"2077_CR115","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1001\/jamacardio.2016.1170","volume":"1","author":"Z Hijazi","year":"2016","unstructured":"Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial. JAMA Cardiol. 2016;1(4):451\u201360. https:\/\/doi.org\/10.1001\/jamacardio.2016.1170.","journal-title":"JAMA Cardiol."},{"issue":"3","key":"2077_CR116","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1053\/j.ajkd.2022.07.017","volume":"81","author":"M Trevisan","year":"2023","unstructured":"Trevisan M, Hjemdahl P, Clase CM, et al. Cardiorenal outcomes among patients with atrial fibrillation treated with oral anticoagulants. Am J Kidney Dis. 2023;81(3):307-317.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2022.07.017.","journal-title":"Am J Kidney Dis"},{"issue":"24","key":"2077_CR117","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1182\/blood-2010-01-264598","volume":"115","author":"RJ Rennenberg","year":"2010","unstructured":"Rennenberg RJ, van Varik BJ, Schurgers LJ, et al. Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood. 2010;115(24):5121\u20133. https:\/\/doi.org\/10.1182\/blood-2010-01-264598.","journal-title":"Blood"},{"issue":"2","key":"2077_CR118","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/rth2.12189","volume":"3","author":"F Posch","year":"2019","unstructured":"Posch F, Ay C, St\u00f6ger H, Kreutz R, Beyer-Westendorf J. Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. Res Pract Thromb Haemost. 2019;3(2):207\u201316. https:\/\/doi.org\/10.1002\/rth2.12189.","journal-title":"Res Pract Thromb Haemost."},{"issue":"8","key":"2077_CR119","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012195","volume":"8","author":"H Ichikawa","year":"2019","unstructured":"Ichikawa H, Shimada M, Narita M, et al. Rivaroxaban, a direct factor Xa inhibitor, ameliorates hypertensive renal damage through inhibition of the inflammatory response mediated by protease-activated receptor pathway. J Am Heart Assoc. 2019;8(8): e012195. https:\/\/doi.org\/10.1161\/JAHA.119.012195.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"2077_CR120","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1053\/j.ajkd.2018.04.005","volume":"73","author":"RR Townsend","year":"2019","unstructured":"Townsend RR. Arterial stiffness in CKD: a review. Am J Kidney Dis. 2019;73(2):240\u20137. https:\/\/doi.org\/10.1053\/j.ajkd.2018.04.005.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2077_CR121","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/ki.2012.477","volume":"83","author":"KM McCabe","year":"2013","unstructured":"McCabe KM, Booth SL, Fu X, et al. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 2013;83(5):835\u201344. https:\/\/doi.org\/10.1038\/ki.2012.477.","journal-title":"Kidney Int"},{"issue":"6","key":"2077_CR122","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1053\/j.ackd.2019.10.005","volume":"26","author":"M Cozzolino","year":"2019","unstructured":"Cozzolino M, Fusaro M, Ciceri P, Gasperoni L, Cianciolo G. The role of vitamin K in vascular calcification. Adv Chronic Kidney Dis. 2019;26(6):437\u201344. https:\/\/doi.org\/10.1053\/j.ackd.2019.10.005.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"11","key":"2077_CR123","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/ndt\/gfu224","volume":"29","author":"F Mac-Way","year":"2014","unstructured":"Mac-Way F, Poulin A, Utescu MS, et al. The impact of warfarin on the rate of progression of aortic stiffness in hemodialysis patients: a longitudinal study. Nephrol Dial Transplant. 2014;29(11):2113\u201320. https:\/\/doi.org\/10.1093\/ndt\/gfu224.","journal-title":"Nephrol Dial Transplant"},{"key":"2077_CR124","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ijcard.2018.11.119","volume":"278","author":"L Di Lullo","year":"2019","unstructured":"Di Lullo L, Tripepi G, Ronco C, et al. Cardiac valve calcification and use of anticoagulants: preliminary observation of a potentially modifiable risk factor. Int J Cardiol. 2019;278:243\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2018.11.119.","journal-title":"Int J Cardiol"},{"issue":"2","key":"2077_CR125","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/ckj\/sfv146","volume":"9","author":"R Caluw\u00e9","year":"2016","unstructured":"Caluw\u00e9 R, Pyfferoen L, De Boeck K, De Vriese AS. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. Clin Kidney J. 2016;9(2):273\u20139. https:\/\/doi.org\/10.1093\/ckj\/sfv146.","journal-title":"Clin Kidney J"},{"issue":"12","key":"2077_CR126","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.amjmed.2016.08.019","volume":"129","author":"R Fernandez-Prado","year":"2016","unstructured":"Fernandez-Prado R, Castillo-Rodriguez E, Velez-Arribas FJ, Gracia-Iguacel C, Ortiz A. Creatinine clearance is not equal to glomerular filtration rate and cockcroft-gault equation is not equal to CKD-EPI collaboration equation. Am J Med. 2016;129(12):1259\u201363. https:\/\/doi.org\/10.1016\/j.amjmed.2016.08.019.","journal-title":"Am J Med"},{"issue":"15","key":"2077_CR127","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.jacc.2020.08.025","volume":"76","author":"YH Chan","year":"2020","unstructured":"Chan YH, Chao TF, Lee HF, et al. Impacts of different renal function estimation formulas on dosing of DOACs and clinical outcomes. J Am Coll Cardiol. 2020;76(15):1808\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.025.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2077_CR128","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2024 Jan 2;149(1):e167] [published correction appears in Circulation. 2024 Feb 27;149(9):e936]. Circulation. 2024;149(1):e1\u2013156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193.","journal-title":"Circulation"},{"issue":"3","key":"2077_CR129","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1161\/ATVBAHA.108.162545","volume":"28","author":"JA Heit","year":"2008","unstructured":"Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28(3):370\u20132. https:\/\/doi.org\/10.1161\/ATVBAHA.108.162545.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2077_CR130","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1681\/ASN.2007030308","volume":"19","author":"K Wattanakit","year":"2008","unstructured":"Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008;19(1):135\u201340. https:\/\/doi.org\/10.1681\/ASN.2007030308.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2077_CR131","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1159\/000497436","volume":"28","author":"V \u0122\u012bbietis","year":"2019","unstructured":"\u0122\u012bbietis V, Kigitovi\u010da D, V\u012btola B, Strautmane S, Skride A. Glomerular filtration rate as a prognostic factor for long-term mortality after acute pulmonary embolism. Med Princ Pract. 2019;28(3):264\u201372. https:\/\/doi.org\/10.1159\/000497436.","journal-title":"Med Princ Pract"},{"issue":"10","key":"2077_CR132","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.22886","volume":"3","author":"S Goto","year":"2020","unstructured":"Goto S, Haas S, Ageno W, et al. Assessment of outcomes among patients with venous thromboembolism with and without chronic kidney disease. JAMA Netw Open. 2020;3(10): e2022886. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.22886.","journal-title":"JAMA Netw Open"},{"issue":"19","key":"2077_CR133","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.202000183","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, Hutten BA, Jaff MR, Manja V, Schulman S, Thurston C, Vedantham S, Verhamme P, Witt DM, Florez I, Izcovich A, Nieuwlaat R, Ross S, Sch\u00fcnemann H, Wiercioch W, Zhang Y, Zhang Y. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693\u2013738. https:\/\/doi.org\/10.1182\/bloodadvances.202000183.","journal-title":"Blood Adv"},{"issue":"2 Suppl","key":"2077_CR134","doi-asserted-by":"publisher","first-page":"e419S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S-e496S. https:\/\/doi.org\/10.1378\/chest.11-2301.","journal-title":"Chest"},{"issue":"6","key":"2077_CR135","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545\u2013608. https:\/\/doi.org\/10.1016\/j.chest.2021.07.055.","journal-title":"Chest"},{"key":"2077_CR136","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1477-9560-12-25","volume":"12","author":"RM Bauersachs","year":"2014","unstructured":"Bauersachs RM, Lensing AW, Prins MH, et al. Rivaroxaban versus enoxaparin\/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J. 2014;12:25. https:\/\/doi.org\/10.1186\/1477-9560-12-25.","journal-title":"Thromb J"},{"issue":"4","key":"2077_CR137","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1160\/TH16-03-0244","volume":"116","author":"P Verhamme","year":"2016","unstructured":"Verhamme P, Wells PS, Segers A, et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost. 2016;116(4):747\u201353. https:\/\/doi.org\/10.1160\/TH16-03-0244.","journal-title":"Thromb Haemost"},{"issue":"11","key":"2077_CR138","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1160\/TH17-03-0176","volume":"117","author":"SZ Goldhaber","year":"2017","unstructured":"Goldhaber SZ, Schulman S, Eriksson H, et al. Dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of RE-COVER and RE-COVER II. Thromb Haemost. 2017;117(11):2045\u201352. https:\/\/doi.org\/10.1160\/TH17-03-0176.","journal-title":"Thromb Haemost"},{"issue":"5","key":"2077_CR139","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2215\/CJN.03410322","volume":"17","author":"TA Mavrakanas","year":"2022","unstructured":"Mavrakanas TA. Treatment options for venous thromboembolism in patients receiving dialysis. Clin J Am Soc Nephrol. 2022;17(5):623\u20135. https:\/\/doi.org\/10.2215\/CJN.03410322.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2077_CR140","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","volume":"61","author":"SK Kakkos","year":"2021","unstructured":"Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, Ten Cate-Hoek AJ, Elalamy I, Enzmann FK, Geroulakos G, Gotts\u00e4ter A, Hunt BJ, Mansilha A, Nicolaides AN, Sandset PM, Stansby G. Editor\u2019s Choice\u2014European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg. 2021;61(1):9\u201382. https:\/\/doi.org\/10.1016\/j.ejvs.2020.09.023.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"10","key":"2077_CR141","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/jhm.12926","volume":"17","author":"MI Ellenbogen","year":"2022","unstructured":"Ellenbogen MI, Ardeshirrouhanifard S, Segal JB, Streiff MB, Deitelzweig SB, Brotman DJ. Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: a national cohort study. J Hosp Med. 2022;17(10):809\u201318. https:\/\/doi.org\/10.1002\/jhm.12926.","journal-title":"J Hosp Med"},{"issue":"5","key":"2077_CR142","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2215\/CJN.14021021","volume":"17","author":"JB Wetmore","year":"2022","unstructured":"Wetmore JB, Herzog CA, Yan H, Reyes JL, Weinhandl ED, Roetker NS. Apixaban versus warfarin for treatment of venous thromboembolism in patients receiving long-term dialysis. Clin J Am Soc Nephrol. 2022;17(5):693\u2013702. https:\/\/doi.org\/10.2215\/CJN.14021021.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2077_CR143","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1097\/TP.0000000000004452","volume":"107","author":"TAJ van den Berg","year":"2023","unstructured":"van den Berg TAJ, Nieuwenhuijs-Moeke GJ, Lisman T, Moers C, Bakker SJL, Pol RA. Pathophysiological changes in the hemostatic system and antithrombotic management in kidney transplant recipients. Transplantation. 2023;107(6):1248\u201357. https:\/\/doi.org\/10.1097\/TP.0000000000004452.","journal-title":"Transplantation"},{"issue":"3","key":"2077_CR144","doi-asserted-by":"publisher","first-page":"11557","DOI":"10.1002\/14651858.CD011557.pub2","volume":"3","author":"V Surianarayanan","year":"2021","unstructured":"Surianarayanan V, Hoather TJ, Tingle SJ, Thompson ER, Hanley J, Wilson CH. Interventions for preventing thrombosis in solid organ transplant recipients. Cochrane Database Syst Rev. 2021;3(3):11557. https:\/\/doi.org\/10.1002\/14651858.CD011557.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2077_CR145","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14021","volume":"25","author":"S Bapistella","year":"2021","unstructured":"Bapistella S, Zirngibl M, Buder K, Toulany N, Laube GF, Weitz M. Prophylactic antithrombotic management in adult and pediatric kidney transplantation: a systematic review and meta-analysis. Pediatr Transplant. 2021;25(4): e14021. https:\/\/doi.org\/10.1111\/petr.14021.","journal-title":"Pediatr Transplant"},{"issue":"8","key":"2077_CR146","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/ctr.12573","volume":"29","author":"A Jonsson","year":"2015","unstructured":"Jonsson A, Kayler LK. Kidney transplantation without interruption of warfarin. Clin Transplant. 2015;29(8):665\u20136. https:\/\/doi.org\/10.1111\/ctr.12573.","journal-title":"Clin Transplant"},{"issue":"11","key":"2077_CR147","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/ndt\/gfu216","volume":"30","author":"D Abramowicz","year":"2015","unstructured":"Abramowicz D, Cochat P, Claas FH, et al. European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant. 2015;30(11):1790\u20137. https:\/\/doi.org\/10.1093\/ndt\/gfu216.","journal-title":"Nephrol Dial Transplant"},{"key":"2077_CR148","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.931648","volume":"26","author":"JC Alonso-Escalante","year":"2021","unstructured":"Alonso-Escalante JC, Machado L, Tabar KR, Tindall R, Thai N, Uemura T. Is continuing anticoagulation or antiplatelet therapy safe prior to kidney transplantation? Ann Transplant. 2021;26: e931648. https:\/\/doi.org\/10.12659\/AOT.931648.","journal-title":"Ann Transplant"},{"issue":"4","key":"2077_CR149","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/ckj\/sfaa057","volume":"14","author":"A Santos","year":"2020","unstructured":"Santos A, Mac\u00edas N, Vega A, et al. Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration. Clin Kidney J. 2020;14(4):1120\u20135. https:\/\/doi.org\/10.1093\/ckj\/sfaa057.","journal-title":"Clin Kidney J"},{"issue":"5","key":"2077_CR150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097187","volume":"9","author":"B Gu\u00e9ry","year":"2014","unstructured":"Gu\u00e9ry B, Alberti C, Servais A, Harrami E, Bererhi L, Zins B, Touam M, Joly D. Hemodialysis without systemic anticoagulation: a prospective randomized trial to evaluate 3 strategies in patients at risk of bleeding. PLoS ONE. 2014;9(5): e97187. https:\/\/doi.org\/10.1371\/journal.pone.0097187.","journal-title":"PLoS ONE"},{"issue":"2","key":"2077_CR151","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1053\/ajkd.2002.30551","volume":"39","author":"P Evenepoel","year":"2002","unstructured":"Evenepoel P, Maes B, Vanwalleghem J, Kuypers D, Messiaen T, Vanrenterghem Y. Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. Am J Kidney Dis. 2002;39(2):315\u201323. https:\/\/doi.org\/10.1053\/ajkd.2002.30551.","journal-title":"Am J Kidney Dis"},{"key":"2077_CR152","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijcard.2022.07.022","volume":"366","author":"Y Lang","year":"2022","unstructured":"Lang Y, Zheng Y, Qi B, et al. Anticoagulation with nafamostat mesilate during extracorporeal life support. Int J Cardiol. 2022;366:71\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2022.07.022.","journal-title":"Int J Cardiol"},{"issue":"2","key":"2077_CR153","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4266\/acc.2021.01312","volume":"37","author":"JH Lee","year":"2022","unstructured":"Lee JH, Park JH, Jang JH, et al. The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation. Acute Crit Care. 2022;37(2):177\u201384. https:\/\/doi.org\/10.4266\/acc.2021.01312.","journal-title":"Acute Crit Care."},{"issue":"52","key":"2077_CR154","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002392","volume":"94","author":"JY Choi","year":"2015","unstructured":"Choi JY, Kang YJ, Jang HM, et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine (Baltimore). 2015;94(52): e2392. https:\/\/doi.org\/10.1097\/MD.0000000000002392.","journal-title":"Medicine (Baltimore)"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02077-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02077-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02077-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T15:06:38Z","timestamp":1729955198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02077-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":154,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2077"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02077-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"assertion":[{"value":"25 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marco Montomoli, Boris Gonzales Cand\u00eda, Adriana Acosta Barrios, and Elisa Perez Bernat declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors have made substantial contributions to the conception, design of the work; the acquisition, analysis, and interpretation of data; have drafted the work or substantively revised it; have approved the submitted version (and any substantially modified version that involves the author's contribution to the study); and have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}